Aspire Pharmaceuticals
Aspire Pharmaceuticals, a leading player in the pharmaceutical industry, is headquartered in the United States and operates across various regions globally. Founded in 2005, the company has made significant strides in developing innovative therapies, particularly in the fields of neurology and pain management. Aspire Pharmaceuticals is renowned for its unique portfolio of products, which includes advanced formulations that address unmet medical needs. The company’s commitment to research and development has positioned it as a trusted name in the market, with notable achievements in clinical trials and regulatory approvals. With a focus on improving patient outcomes, Aspire Pharmaceuticals continues to expand its reach and influence within the healthcare sector, solidifying its reputation as a forward-thinking organisation dedicated to enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Aspire Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Metal Fabrication industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aspire Pharmaceuticals's score of 10 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aspire Pharmaceuticals's reported carbon emissions
In 2023, Aspire Pharmaceuticals reported total carbon emissions of approximately 1,021,060 kg CO2e in the UK. This figure includes 81,270 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and 82,840 kg CO2e from Scope 2 emissions. The majority of their emissions, about 957,180 kg CO2e, fall under Scope 3, which encompasses business travel (69,950 kg CO2e), employee commuting (529,920 kg CO2e), waste generated in operations (7,920 kg CO2e), and upstream transportation and distribution (328,470 kg CO2e). In comparison, the previous year, 2022, saw total emissions of approximately 2,155,520 kg CO2e, indicating a significant reduction in emissions. The breakdown for 2022 included 14,170 kg CO2e from Scope 1, 66,840 kg CO2e from Scope 2, and a substantial 2,141,350 kg CO2e from Scope 3. Despite these reductions, Aspire Pharmaceuticals has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). Their climate commitments remain vague, and further details on their long-term strategies for carbon reduction are not specified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | 115,130 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aspire Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
